Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Deltyba
Delamanid is an antimycobacterial drug used in combination with other medications to treat multidrug-resistant tuberculosis (MDR-TB). It belongs to a new class of drugs called nitroimidazooxazines and works by inhibiting the synthesis of mycolic acids, essential components of the mycobacterial cell wall. Delamanid is typically reserved for cases where other treatment options have failed due to drug resistance.
For the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults.
QT prolongation. Delamanid can prolong the QT interval, increasing the risk of life-threatening arrhythmias. Electrocardiograms (ECGs) should be performed before starting treatment, monthly during treatment, and at the end of treatment.
Outcome:
Decreased delamanid concentrations
Mechanism:
Induction of CYP3A4 enzyme
Outcome:
Increased midazolam concentrations
Mechanism:
Inhibition of CYP3A4 enzyme
Outcome:
Slight decrease in delamanid absorption
Mechanism:
Increased gastric pH
Most likely new formulation: extended-release delamanid (Year: 2026, 75% confidence)
Based on current usage and clinical trial data, there is a 90% likelihood of delamanid remaining a key component of MDR-TB treatment regimens for the next 5 years.
Antimycobacterial, Nitroimidazooxazine
Nitroimidazooxazine